



CDC-recommended sequential administration and intervals for immunocompetent adults aged ≥ 65 years^{1,a,b}


Pneumococcal vaccine-naïve persons aged ≥ 65 years



Persons who previously received PNEUMOVAX 23 at age ≥ 65 years



Persons who previously received PNEUMOVAX 23 before age 65 years who are now aged ≥ 65 years



CDC=Centers for Disease Control and Prevention.

PCV13=13-valent pneumococcal conjugate vaccine.

PPSV23=23-valent pneumococcal polysaccharide vaccine.

^aIf a dose of PNEUMOVAX 23 is given earlier than the recommended interval, the dose need not be repeated.

^bPNEUMOVAX 23 and PCV13 should not be coadministered.

Important considerations:

- There are limited data on the sequential administration of PNEUMOVAX 23 with other vaccines, including PCV13.
- An immunogenicity study described in the Prescribing Information for PCV13 evaluated the sequential administration with PNEUMOVAX 23 in adults aged 60–64 years²:
 - Diminished immune response with one dose of PNEUMOVAX 23 followed by a dose of PCV13 one year later vs PCV13 alone
 - Noninferior immune response with one dose of PCV13 followed by a dose of PNEUMOVAX 23 one year later vs PNEUMOVAX 23 alone
- The levels of antibodies that correlate with protection against pneumococcal disease have not been clearly defined.
- Routine revaccination of immunocompetent persons previously vaccinated with a 23-valent vaccine is not recommended.
- For subjects aged ≥ 65 years in a clinical study, systemic adverse reactions which were determined by the investigator to be vaccine-related were higher following revaccination with PNEUMOVAX 23 than following initial vaccination with PNEUMOVAX 23.

PNEUMOVAX 23 is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).

PNEUMOVAX 23 is approved for use in persons 50 years of age or older and persons aged ≥ 2 years who are at increased risk for pneumococcal disease.

PNEUMOVAX 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine.

Select Safety Information

Do not administer PNEUMOVAX 23 to individuals with a history of a hypersensitivity reaction to any component of the vaccine.

Defer vaccination with PNEUMOVAX 23 in persons with moderate or severe acute illness.

Use caution and appropriate care in administering PNEUMOVAX 23 to individuals with severely compromised cardiovascular and/or pulmonary function in whom a systemic reaction would pose a significant risk.

Since elderly individuals may not tolerate medical interventions as well as younger individuals, a higher frequency and/or a greater severity of reactions in some older individuals cannot be ruled out.

Persons who are immunocompromised, including persons receiving immunosuppressive therapy, may have a diminished immune response to PNEUMOVAX 23.

The most common adverse reactions, reported in $>10\%$ of subjects vaccinated with PNEUMOVAX 23 in clinical trials, were: injection-site pain/soreness/tenderness, injection-site swelling/induration, headache, injection-site erythema, asthenia and fatigue, and myalgia.

For subjects aged 65 years or older in a clinical study, systemic adverse reactions which were determined by the investigator to be vaccine-related were higher following revaccination than following initial vaccination.

Vaccination with PNEUMOVAX 23 may not offer 100% protection from pneumococcal infection.

Before administering PNEUMOVAX 23, please read the accompanying [Prescribing Information](#). The [Patient Information](#) also is available.

For additional copies of the Prescribing Information, please call 800-672-6372, visit [MerckVaccines.com](#)[®], or contact your Merck representative.

References: 1. Centers for Disease Control and Prevention (CDC). Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep.* 2015;64(34):944–947. (Erratum Notice: CDC. *MMWR Morb Mortal Wkly Rep.* 2015;64(42):1204.). 2. Prevnar 13 [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; 2017. 3. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥ 65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep.* 2014;63(37):822–825.

PNEUMOVAX²³
(Pneumococcal Vaccine Polyvalent)

According to the CDC—
**Sequential vaccination with both PCV13
and PNEUMOVAX 23 is recommended³**

